MENU

Call for Abstracts

Stay in the Know
Get the latest news on exciting speakers, workshops & learning opportunities at ICNMD 2022.

Subscribe for Updates

Abstract Submission Now Closed

The Program Committee for the ICNMD 2022 Congress thanks you for your submission of scientific abstracts.

The extended deadline for all submissions is 4 February 2022 (23:59 GMT+1). 

Important Deadline

Call For Abstract Closed
Abstract Acceptance Notification 16 March 2022
Presenting Author Registration Deadline 25 March 2022

 

Submission Guidelines

    Update: Accepted abstracts will be published in the Journal of Neuromuscular Diseases (JND).

  • Abstracts will be accepted in English only.
  • Encore Abstracts will not be accepted.
  • The maximum word limit for Abstract title is 15 (excluding spaces).
  • The maximum word limit for Abstract text is 500 (excluding spaces).
  • An international panel of reviewers will review all abstracts
  • Abstracts can only be submitted online, via the submission portal. Paper, eMail submission and USB/CD submission will NOT be accepted. Please click HERE to view the step by step abstract submission guide.
  • Submitting an abstract does not register you for ICNMD2022; Presenting Authors must register for the Congress.
  • ICNMD2022 organizers expect that all abstracts selected for presentation will be presented by the authors and that submitted abstracts will not be withdrawn.
  • Please do not submit an abstract if you are not able to travel to the Congress and present it in the form selected.
  • Case reports presented as abstract for poster display are accepted.
  • All authors must complete a conflict of interest on their abstract submission.
  • If your research has been granted any commercial or institutional support, you will be asked to disclose this during the submission process.
  • Posters by representatives of commercial companies are accepted with the authors’ names (and any professional designation such as MD, or Researcher etc.) only, and are not to include names or associations with the commercial companies that they represent. Generic product names may be used but not company product names.
  • Please note, all abstracts are submitted as a poster presentation and the posters with the top scores will be invited to present their work in one of the sessions at ICNMD 2022.

 

Submission Categories

ACQUIRED

  • Inflammatory / Immune-mediated Myopathies/Inclusion Body Myopathies: sIBM,
  • Toxic / Endocrine / Other Acquired Myopathies
  • Advances in treatment of muscle diseases.
  • Other Myopathies

GENETIC

  • Dystrophinopathies
  • Muscle Dystrophies (Non-Dystrophinopathies)
  • Congenital Myopathies
  • Myotonic Dystrophies
  • Muscle Channelopathies and Related Disorders
  • Facioscapulohumeral Muscular Dystrophies
  • Oculopharyngeal Muscular Dystrophy/Oculopharyngodistal Myopathies
  • Metabolic Myopathies (non-mitochondrial): Glycogen, Lipids
  • Mitochondrial Myopathies
  • Distal Myopathies
  • Myofibrillar Myopathies/hIBM
  • Advances in treatment of muscle diseases.
  • Other Myopathies
  • Myasthenia Gravis
  • Myasthenic Syndromes
  • Congenital Myasthenia
  • Advances in treatment of Neuromuscular Junction diseases
  • Hereditary Peripheral Neuropathies
  • Immune-mediated Neuropathies
  • Neuropathies Associated with Monoclonal Gammopathy / Paraneoplastic
  • Metabolic, Toxic and Iatrogenic Neuropathies
  • Infectious Peripheral Neuropathies (including Leprosy, HIV)
  • Advances in treatment of Peripheral Neuropathies
  • Small fibers and painful neuropathies
  • Autonomic neuropathies
  • Complex/syndromic neuropathies: Hereditary ataxias/spastic paraplegias
  • Others
  • ALS: Epidemiology and Clinical Features,
  • ALS: Biology, Pathophysiology, Genetics
  • ALS: Therapy
  • Primary Progressive Lateral Sclerosis Variant
  • non 5q SMA/distal SMA/ Hereditary Motor Neuropathies
  • Poliomyelitis
  • Bulbospinal muscular atrophy
  • Biomarkers in MND
  • Spinal Muscular Atrophies: Epidemiology and Clinical Features,
  • Spinal Muscular Atrophies: Pathophysiology, Genetics
  • Spinal Muscular Atrophies: Treatment
  • Advances in treatment of Motor Neuron Diseases
  • Ultrasound
  • MRI
  • Electrophysiology
  • Neuromuscular Pathology: Muscle and Nerve Biopsy
  • Genetics in Neuromuscular Diseases including Biochemical/Molecular Techniques and next generation sequencing.
  • Small Nerve Fibre Evaluation by Skin Biopsy
  • Other Biomarkers
  • Swallowing evaluation in neuromuscular diseases
  • Cardiac and respiratory issues in neuromuscular diseases.
  • Orthopedic issues in neuromuscular diseases.
  • Outcome measures and clinimetry
  • Muscle Homeostasis / Muscle Regeneration
  • Muscle Structure / Muscle Development / Muscle Growth
  • Muscle Atrophy / Degeneration
  • Nuclear Envelope / Nuclear Matrix of Muscle Cell
  • Ion Channel Function in Neuron and Muscle
  • Nerve development/nerve degeneration and regeneration
  • Mechanisms of myelination and demyelination
  • Immune Mechanisms in Neuromuscular Diseases
  • Fundamental Approaches to Motor Neuron, Axon and Related Structures
  • Neuromuscular Junction
  • Axonal transport / axonal degeneration
  • Myelin and Schwann cell

Contact

For any inquiries, please contact icnmd2022-program@icsevents.com. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.




Stay Up to Date!
Receive the latest information about the International Congress on Neuromuscular Diseases by entering your information below.
X